Team:SupBiotech-Paris/Treatement modeling

From 2009.igem.org

Revision as of 00:01, 22 October 2009 by Gaella (Talk | contribs)

framless


Contents

Modelling of DVS efficiency on a lung tumour

Context

Non-small cell lung carcinoma, or NSCLC, is an aggressive cancer, with a relatively high speed growth. Treatments are often ineficient, because the tumour growth is faster than the elimination by the drug

Objective

We have decided to model our treatment efficacy for this kind of tumour. Therefore we have modelled the tumour progression, our treatment evolution and efficacy. The objective of the modelling is to verify if our treatment is able to eliminate the entire tumour.

Back to top

Model segmentation

First, we had to recreate DVS complete mechanism and the tumour evolution. Then, for each step of the treatment, we have identified all the paramters that intervene, their actions and their interactions, in order to determine the model equations.

To simplifly the equation we have devided the mechanism and we have modelled each step separately.


Back to top

Tumor and DVS evolution versus time

First step : Tumour development according to time

We consider the tumour is non métastatic and its growth is exponential.
Let the tumour have a volume V1 in cm3 at an instant t1.
Let the same tumour, at an instant t2, have a volume V2.
The tumour is considered in exponetial growth phase and without metastasis therefore its development equation, Tumor Growth Rate (TGR), is equal to :

TGR.jpg

Thus, thetumour volume according to the time (V(t)) is equal to :

V(t).jpg

Finally, knowing the Average volume of a cancerous cell (Vcc) (experimental data), if we regard the tumour as fraught (without cavity or blood vessel), we can determine that the Number of cancerous cells according to time (Nc(t)), without treatment effect, is equal to :

N(c).jpg


Back to top

Second step : Development of the tissue vector

The tissue vector is injected to the patient at an instant t, near t2. The Number of injected vectors (Nbi) is 1x10^6. The pulmonary tropism of the vector isn’t perfect, only a Percentage (Pp) goes to the lung. The total number of tissue vector in the body increases, because this vector is bacterial and therefore possesses a Doubling period (DTB).
Thus we can establish that the tissue vector number in the lungs (Nb(t)) is equal to:

Nb(t).jpg

The number of Tissue vectors increases until injection of doxycycline. F rom then, tissue vectors lysis releases the cell vectors in the lung.

This injection time is not insignificant. Indeed, si if we wait long enough, tissue vectors number is sufficient to eliminate the tumour or at least to significantly reduce it. On the other hand, if we wait too long, a higher dose of doxycycline (and so potentially toxic) is necessary for cell vector release.

Thus we can use modelling to determine the optimal injection time of doxycyline (Tdox).


Back to top

Third step : Release of the cell vector

Once the doxycycline injected, the cell vector is released. The cell vectors number is proportional to the tissue vectors number in the lung. And yet, we know the average value of recombinant phage vectors released by M. avium (Npl) is equal to 100.
We can write cell vectors number at the injection instant (Np(Tdox)) is equal to :

Np(t)1.jpg

The cell vectors number does not increase such as the tissue vectors. Indeed, it decreases with time, because of the phage vector stability and of its cell penetration (to release the therapeutic plasmide).
Its stability in the blood is equal to the phage vector deterioration constant (kdeg) according to time. If we add this constant to the cell vectors number equation according to time (Np(t)) we obtain the following formula :

Np(t)2.jpg

The phage vector dispersion steps in the tumour and for cell penetration are the steps below Fourth and Fifth) because of their complexity.


Back to top

DVS Efficiency

So, we determined:

  • The size of the tumor versus time (initial volume + growth)
  • The amount of tissue vector versus time
  • The amount of released cell vectors for a tissue vector

Now, we're going to determine the efficiency of our vectors for penetring cancer cells.
For that we are studying:

  • The area of dispersal cell vector
  • The importance of the cellular internalization of the vector in cancer cells.


Back to top

Fourth step : The cell vector dispersion

Here, we are looking for determine the maximum area that a phage can cover. This requires knowing:

  • The spread of phages in the bloodstream
  • Their diffusion through the walls of blood vessels
  • The surface of a cancer cell

For our modeling, we consider the blood as a Newtonian fluid with a constant velocity Vmax. Here, We neglect the heart-related jolts and turbulent flows caused by the cavities of the blood epithelium.

The cell vector moves along two axes. An X axis in the direction of blood flow and a Y axis orthogonal to the axis X.

RepèremouvementmécaniqueEn.png

The phage propagation in the bloodstream

The movement in X depends solely on the propagation of phages the vessel due to blood flow. Indeed, we neglect the diffusion which takes place also along the X axis because it is 1000 times less than the propagation of particles in the blood (due to the importance of blood flow). The cellular carriers are moving at speeds spread on a dish from, Vmax in the center of the vessel at V0 against the vessel wall.

RépartitionvitesseparaboliqueEN.png

The speed of phages decrease in approaching the vessel walls due to the friction forces which are opposing to the movement.

We can determine how long the particle (with a Vmax velocity), ie the particles in the center of the ship, reached the end. This gives the time necessary to internalize all the phages of the bacteria.

The diffusion through the walls of blood vessels

The movement in Y is the distribution of phages in the blood (j(n)). It depends on the equation of diffusion of a particle (n) in a fluid (Fick's Law).

Equation diffusion du phage.png

With n the number of particles (phages), grad n the difference between the concentrations and D the diffusion coefficient. The cellular distribution of vectors within the blood vessel and then through the wall is a phenomenon of diffusion with output. So, there will always be a strong gradient of concentration of phage in the blood. We can therefore say that the gradient is constant (equal to 1) over time. Thus the diffusion rate (j(n)) is equal to D.


Dispersal area of phage

When we combine moving Y (diffusion rate) and moving in X (blood flow velocity), we obtain, after integration on the perimeter of a blood vessel, the action surface of cell vectors. Then, we are able to determine the number of cancer cells per 100 cell vectors destroyed or 1 tissue vector.

The diffusion rate of the cell vector is equal to 0.5 μm.s-1 and the size of a capillary blood is 10μm in diameter. The particle farthest places so 10s to reach the vessel wall.

With this dissemination length (10s), the blood flow velocity (1x10 ^ 3μm.s-1) in the capillaries, and the surface of one cancer cell (1 micron square), we can determine:

  • The length (L) covered by the cell vectors released by one tissue vector.
  • The surface (S) occupied by phages in blood vessel diameter of 2r.
  • The amount of cancer cells available.

L = 1 x 10^4 µm 2r = 10 µm S = 2 x π x L r = 31.4 x 10^4 µm²

Thus, a tissue vector can potentially target more than 31 000 cancer cells, yet it has that 100 cell vectors. We can make a simplification to say that 100 cell vectors destroy 100 cancer cells. The efficiency of the dispersion is complete.

For phage, once reached the wall, comes in the cellular internalization. This model responds to two courses of action.

Back to top

Cinquième étape : L’internalisation du vecteur cellulaire

Une fois au contact de la cellule, le vecteur cellulaire a deux schémas d’action possibles.

  • Le vecteur se fixe puis il se détache de la cellule.
  • Le vecteur se fixe puis il se fait internaliser au sein de la cellule.

On peut modéliser cela en fonction du temps et des Constantes d’Association (kon), de Dissociation (koff) et d’Internalisation (kint).

On obtient ainsi:

EqInt.jpg

Avec kon = 5.10^3 M^-1s^-1, koff = 8.10^-3 s^-1 et kint = 5,78.10^-4 s^-1. Si l’on calcule la constante globale K’, telle que IDP = K’ x t, on obtient K' = 361,5s^-1 Ainsi plus de 360 phages sont internalisés par seconde au contact d’une paroi.

Si l’on compare le temps nécessaire pour internaliser un phages, par rapport au temps d’attente avant que la cellule n’entre en apoptose suite à l’entré d’un vecteur cellulaire (1 heure), il apparait logique de négliger l’internalisation des vecteurs cellulaires (IDP = cte = 360 phages/s ) dans l’équation finale.


Ainsi, avec une efficacité totale de la diffusion des phages, et un temps d’internalisation négligé, on peut dire que la constante d’efficacité λ est égale à 1.


Back to top

Simultaneous evolution of DVS and tumor

The evolution equation of our model over time is equal to:

EqFinale.jpg
float

With :

- Nc (t), the number of cancer cells depending time,
- V (t), tumor volume,
- V1 and V2, two tumor volumes respectively times t1 and t2,
- Vcc, the volume of a cancer cell,
- Nbi, the number of injected vecteurs tissulaires,
- Pp, the lung percentage of vecteurs tissulaires relative to the injected dose,
- DTB, the doubling time of vecteur tissulaire,
- tinj, injection time of the vecteur tissulaire,
- Npl, the number of vecteurs cellulaires released by bactérie.

On peut négliger (aux vues des différences entre les échelles de temps ou d’espace) certains facteurs :

- Kdeg, la constante de dégradation du phage, car tous les phages sont internalisés en 10s.
- D, la diffusion du phage et IDP, l’internalisation cellulaire, car on considère que 100 phages rentrent dans 100 cellules différentes (pour une valeur potentielle de 31400) donc tout cela est égal à 1.


Back to top

Treatment simulation

The DVS need two injection:

  • Injection of DVS,
  • Injection of the activator, doxycycline.

Here's a simulator, which calculates how long must we inject doxycycline to completely eliminate the tumor.


Back to top .